Published in Curr Med Res Opin on October 01, 2005
Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev (2009) 1.39
Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci (2006) 1.28
Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study. Psychopharmacology (Berl) (2010) 0.91
The interaction of escitalopram and R-citalopram at the human serotonin transporter investigated in the mouse. Psychopharmacology (Berl) (2014) 0.89
Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study. Psychopharmacology (Berl) (2007) 0.89
Citalopram versus other anti-depressive agents for depression. Cochrane Database Syst Rev (2012) 0.87
Is escitalopram really relevantly superior to citalopram in treatment of major depressive disorder? A meta-analysis of head-to-head randomized trials. Croat Med J (2010) 0.80
Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population. Neuropsychiatr Dis Treat (2017) 0.78
Qualitative changes in symptomatology as an effect of treatment with escitalopram in generalized anxiety disorder and major depressive disorder. Eur Arch Psychiatry Clin Neurosci (2008) 0.78
Escitalopram--translating molecular properties into clinical benefit: reviewing the evidence in major depression. J Psychopharmacol (2010) 0.77
A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation. J Pharmacokinet Pharmacodyn (2015) 0.77
Efficacy and safety of generic escitalopram (Lexacure(®)) in patients with major depressive disorder: a 6-week multicenter, randomized, rater-blinded, escitalopram-comparative, non-inferiority study. Neuropsychiatr Dis Treat (2015) 0.75
Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med (2010) 6.81
What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? J Clin Psychiatry (2006) 1.48
Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol (2003) 1.34
Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl) (2004) 1.33
Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord (2007) 1.04
Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. Int J Neuropsychopharmacol (2004) 0.98
Escitalopram therapy for major depression and anxiety disorders. Ann Pharmacother (2007) 0.94
Satisfaction with medication is correlated with outcome but not persistence in patients treated with placebo, escitalopram, or serotonin-norepinephrine reuptake inhibitors: a post hoc analysis. Prim Care Companion CNS Disord (2011) 0.94
Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder. Int Clin Psychopharmacol (2008) 0.88
Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes. Ann Clin Psychiatry (2005) 0.84
Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol (2004) 0.84